Masitinib Shows Promise in Progressive MS Treatment, Leading Neurologist Highlights Novel Mechanism of Action
Key Insights
Distinguished neurologist Professor Patrick Vermersch identifies mast and microglia (search) cells as key catalysts in neurodegenerative diseases, highlighting their role in conditions like multiple sclerosis (search) and Alzheimer's disease (search).
AB Science (search)'s masitinib demonstrates potential breakthrough in progressive MS treatment through its unique targeting of innate immune system cells, with Phase III trial data eagerly anticipated.
The drug's novel mechanism of action in targeting both mast cells (search) and microglia (search) offers a promising new approach to managing neuroinflammation in progressive MS, where therapeutic options are currently limited.
AB Science (search)'s leading compound masitinib is emerging as a potential breakthrough treatment for progressive multiple sclerosis (search), according to renowned neurologist Professor Patrick Vermersch. The drug's unique mechanism of action, which targets both mast cells (search) and microglia (search) in the innate immune system, could represent a significant advance in treating this debilitating condition.
Understanding the Role of Neuroinflammation
Professor Vermersch, Director of the Graduate School for Biology and Health at the Université de Lille and one of The Most Influential Leaders in Neurology 2025, emphasizes the central role of neuroinflammation in various neurodegenerative disorders. His research indicates that mast cells (search) and microglia (search), two key components of the innate immune system, act as crucial modulators in the neuroinflammatory process that drives disease progression.
"The pro-inflammatory activity of these cells can serve as a catalyst in the neurodegenerative process," explains Vermersch, highlighting the potential impact of targeting these specific cellular mechanisms in conditions such as multiple sclerosis (search), amyotrophic lateral sclerosis (search), Alzheimer's disease (search), and Parkinson's disease (search).
Masitinib's Novel Therapeutic Approach
The development of masitinib represents a significant departure from conventional treatment approaches. Through its targeted action on both mast cells (search) and microglia (search), the drug addresses a fundamental aspect of disease progression that has previously been underexplored in therapeutic development.
Phase IIB/III trials have yielded promising results, demonstrating masitinib's effectiveness in:
- Reducing neuroinflammation
- Slowing disease progression
- Offering potential long-term benefits for patients
Clinical Implications and Future Prospects
The ongoing Phase III confirmatory study, led by Professor Vermersch, is particularly significant given the limited therapeutic options currently available for progressive MS patients. The study aims to further define which patient populations might benefit most from this innovative treatment approach.
AB Science (search), headquartered in Paris and listed on Euronext Paris, has developed masitinib as part of their protein kinase inhibitor (PKI) portfolio. The company's focus on high unmet medical needs positions this development as particularly significant in the field of neurology.